Boehringer Ingelheim GmbH, of Ingelheim, Germany, said data published in The Lancet Respiratory Medicine showed that levels of eosinophils can help identify patients with chronic obstructive pulmonary disease who may or may not benefit from the addition of an inhaled corticosteroid (ICS) to the treatment regimen.